Emcure Pharmaceuticals Limited | Globe Capital Market LTD.
Emcure Pharmaceuticals Limited
Closed
Price Band
₹960 to ₹1008 per share
IPO Issue Period
July 3, 2024 to July 5, 2024
Issue Size
₹1,952.03 Cr
Face value
₹10 per share
Offer for sale
₹1,152.03 Cr
Fresh issue
₹800.00 Cr
Minimum Shares for Retail
14 Shares
Listing on
BSE, NSE
Issue Type
Book Built Issue IPO
Registrar to the Issue
Link Intime India Private Ltd
Tentative Listing Date
Wednesday, July 10, 2024
QIB
50%
NII
15
Retail
35%

Kotak Mahindra Capital Company Limited
Axis Capital Limited
J.P. Morgan India Private Limited
Jefferies India Private Limited

Emcure Pharmaceuticals Limited, an Indian pharmaceutical company, develops, manufactures, and globally markets a wide range of pharmaceutical products across several major therapeutic areas.

The company has been ranked 13th in domestic sales among pharmaceutical companies in India for MAT September 2023 and 4th in market share in its covered markets for the same period. Additionally, it is the leading pharmaceutical company in gynaecology and HIV antiviral therapeutic areas for the MAT September 2023. In the six months ended September 30, 2023, and the Financial Year 2023, sales in India contributed 50.84% and 53.16% of the company’s total revenue, respectively. The company’s Domestic sales grew at a CAGR of 10.80% between September 2019 and September 2023, outperforming the Indian pharmaceutical market.

For year/ period ended (Rs. in lacs.)

H1FY24 FY23 FY22
Total Revenue 6,715.24 6,031.72 5,918.86
Profit After Tax 527.58 561.85 702.56
EPS 29.68 27.54 36.62
OPM (%) 19.01% 20.24% 23.54%
PATM (%) 7.86% 9.31% 11.81%

 

For year/ period ended ( in Cr.)

Company Name Market Cap (Cr.) Price P/BV P/E Sales (Cr.)
FY23
Net Profits(Cr.)
FY23
Emcure Pharmaceuticals Limited 19029.89 1008 6.18 33.96 6,715.24 527.58
Aurobindo Pharma Ltd. 70,757.95 1,207.60 2.37 22.30 28,704.50 3,186.13
Dr. Reddy’s Laboratories Ltd. 1,06,866.94 6,405.75 3.78 19.16 27,139.60 5,563.20
Lupin Ltd. 73,910.81 1,621.15 5.17 38.61 19,656.34 1,935.57

 

 

  • Well-placed to leverage our position in the domestic market.
  • Demonstrated capabilities of building brands.
  • Large, diversified and fast-growing product portfolio in international markets.
  • Strong R&D capabilities driving differentiated portfolio of products.
  • Extensive and diversified manufacturing capacity.
  • Highly qualified, experienced and entrepreneurial management team and Board.
  • Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by the company; and
  • General corporate purposes

The company is one of the leading pharma Company having niche products and serving global markets. It marked growth in its top lines, but bottom line posted declining trends due to higher interest and depreciation costs. Based on FY24 earnings, the issue appears fully priced. Investors may subscribe for the medium to longer term.

Be a Part of IPO Success Stories!

Never Miss IPO Investment